Summit Therapeutics Inc. (SMMT)
| Market Cap | 15.56B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -746.08M |
| Shares Out | 742.85M |
| EPS (ttm) | -1.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,282,553 |
| Open | 20.30 |
| Previous Close | 20.26 |
| Day's Range | 19.97 - 21.30 |
| 52-Week Range | 15.55 - 36.91 |
| Beta | -1.03 |
| Analysts | Strong Buy |
| Price Target | 33.75 (+61.1%) |
| Earnings Date | Oct 29, 2025 |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for SMMT stock is "Strong Buy." The 12-month stock price target is $33.75, which is an increase of 61.10% from the latest price.
News
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced the grant of inducement awards of options to purchase a collective total of...
HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi-6 trial, conducted in China and sponso...
Ten Bull Market 10-Baggers
While broad market performance has been robust, one striking aspect of this cycle has been the extraordinary gains in a handful of individual equities. Ten stocks in the large-cap Russell 1,000 have n...
Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential
Summit Therapeutics Inc. (SMMT) is a U.S.-based biopharmaceutical company. It focuses on developing innovative medicines for cancer treatment.
Summit Therapeutics Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Summit Therapeutics Inc. investors ("Summit" or the "Company") (NASDAQ: SMMT) investors that the firm has initiated an inv...
CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The original press release, distributed Tuesday, September 9, 2025, incorrectly stated that a lawsuit was filed against Summit Therapeutics, in the head...
Top 3 Health Care Stocks You'll Regret Missing In Q3
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Summit Therapeutics (SMMT) WCLC Update Call (Transcript)
Summit Therapeutics (NASDAQ:SMMT) WCLC Update Conference Call September 08, 2025 08:00 AM Company Participants Dave Gancarz - Chief Business & Strategy Officer Howard (Jack) West - Vice President of ...
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
Summit Therapeutics Inc. SMMT, on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer (WCLC).
New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday.
Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332
The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 In the North American patients, the OS HR was 0.70 The HARMONi trial has already demonstrate...
Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced data from the Phase III HARMONi trial featuring the novel, potential first-...
Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host a call to discuss the ivonescimab data from our global Phase III clinical trial, ...
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
Summit Therapeutics Inc SMMT and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung c...
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi trial featuring the novel, potential f...
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the ...
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $SMMT--SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm.
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics is in advanced talks with AstraZeneca for a potential $15B licensing deal for ivonescimab, boosting its cash runway and strategic position. Ivonescimab shows strong PFS data versus...
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
REDWOOD CITY, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 46th Annual Goldman Sachs Gl...
Summit Therapeutics: Market Overreaction Creates Opportunity
Summit's ivonescimab showed a 48% reduction in disease progression risk in EGFR-mutant lung cancer — a best-in-class result in a tough-to-treat population. Overall survival data is trending positive b...
Is SMMT Stock A Buy After Its Recent Plunge?
Summit Therapeutics (NASDAQ: SMMT) experienced a significant 30% decrease in its stock on Friday, May 30th, closing at $18. This sudden decline came even though the stock had doubled within the past y...
Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release
PFS in Phase 3 HARMONi study, using ivonescimab + chemotherapy to treat patients with EGFR 2nd-line NSCLC, was met with statistical significance, but OS was not. OS data not being met in a statistical...
Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.
The trial was meant to answer the biggest question in biotech: What happens when U.S. companies test promising new Chinese cancer immunotherapies in western countries?
Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint
Summit Therapeutics Inc. SMMT released topline results on Friday from the Phase 3 HARMONi trial of ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherapy...